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SUMMARY 
 
Melanoma has a propensity to metastasize to bone, where it is exposed to high concentrations 
of TGF-β. Because TGF-β promotes bone metastases from other solid tumors such as breast 
cancer, we tested the role of TGF-β in melanoma metastases to bone. 1205Lu melanoma 
cells, stably transfected to overexpress the natural TGF-β/Smad signaling inhibitor Smad7, 
were studied in an experimental model of bone metastasis whereby tumor cells are inoculated 
into the left cardiac ventricle of nude mice. All mice bearing parental and mock-transfected 
1205Lu cells developed osteolytic bone metastases 5 weeks post tumor inoculation.  Mice 
bearing 1205Lu-Smad7 tumors had significantly less osteolysis on radiographs and longer 
survival compared to parental and mock-transfected 1205Lu mice. To determine if the 
reduced bone metastases observed in mice bearing 1205Lu-Smad7 clones was due to reduced 
expression of TGF-β target genes known to enhance metastases to bone from breast cancer 
cells, we analyzed gene expression of osteolytic factors, PTHrP and IL-11, the chemotactic 
receptor CXCR4, and osteopontin in 1205Lu cells. Quantitative RT-PCR analysis indicated 
that PTHrP, IL-11, CXCR4, and osteopontin mRNA steady-state levels were robustly 
increased in response to TGF-β, and that Smad7, and the TβRI small molecule inhibitor, 
SB431542, prevented such induction. Also, 1205Lu-Smad7 metastases expressed 
significantly lower levels of IL-11, CTGF and PTHrP. These data suggest that TGF-β 
promotes osteolytic bone metastases due to melanoma by stimulating the expression of 
prometastatic factors via the Smad pathway. Blockade of TGF-β signaling may be an 
effective treatment for melanoma metastasis to bone. 
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INTRODUCTION 
 
Transforming growth factor (TGF)-β is a prototypic multifunctional cytokine whose broad 
modulatory activity affects numerous biological functions. At the organism level, these 
include, but are not limited to, control of immune functions, embryogenesis, carcinogenesis 
and tissue responses to injury. At the cell level, TGF-β controls proliferation, migration, as 
well as extracellular matrix (ECM) synthesis and degradation (1-5). The complexity of the 
role played by TGF-β in cancer and metastasis is underscored by the duality of this growth 
factor, depending on the stage of the disease (6-8). Thus, even though the TGF-β signaling 
cascade functions as a tumor suppressor pathway in early carcinogenesis, mainly through the 
ability of TGF-β to inhibit the cell cycle, it paradoxically favors tumor progression during 
late-stage metastatic progression of tumors.   
TGF-β signal transduction occurs via ligand-activated heterotetrameric serine/threonine 
kinase receptors (TβRI and TβRII) on the cell surface, which phosphorylate the cytoplasmic 
proteins Smad2 and Smad3. These receptor-regulated Smads (R-Smads) are ligand-specific 
and, upon activation, associate with Smad4, a common partner to all receptor-regulated 
Smads activated by the various ligands of the TGF-β family. R-Smad/Smad4 
heterocomplexes then translocate into the cell nucleus to regulate target gene transcription (5, 
9). The inhibitory Smad, Smad7, interferes with Smad signaling by various means: (a), it 
binds activated TβRI to prevent phosphorylation of Smad2/3; (b), it recruits E3 ubiquitin-
ligases such as Smurf1, Smurf2 and WWP1, to the activated TGF-β receptor complexes, 
leading to their proteasomal degradation; (c), it interacts with GADD34, the regulatory 
subunit of the protein phosphatase PP1, thereby recruiting it to TβRI to inactivate the latter 
(10-12). 
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The impact of TGF-β on melanoma progression is just beginning to unravel. Malignant 
melanomas secrete high amounts of TGF-β, whose autocrine and paracrine effects contribute 
directly and indirectly to tumor progression (13). Indeed, we previously identified that 
melanoma cell-derived TGF-β results in high, ligand-dependent, constitutive Smad3-driven 
transcriptional activity (14). Also, we identified that overexpression of Smad7 inhibits 
melanoma cell MMP-2 and MMP-9 production, dramatically impairs their invasive capacity 
in vitro, reduces anchorage-independent growth, and delays subcutaneous tumor growth in 
nude mice (15). These findings underscore the notion that intact, or exacerbated, Smad 
signaling occurs throughout tumor progression in melanoma cells. 
In experimental models of metastasis, it has been shown that TGF-β is essential for breast 
cancer cells to form bone metastases (16, 17). Furthermore,  the release of TGF-β from the 
bone matrix upon activation of osteoclasts by soluble factors, such as parathyroid hormone-
related protein (PTHrP) derived from cancer cells, further exacerbates the latter and enhances 
the growth of metastases, thereby establishing what has been viewed as a vicious cycle 
orchestrated by TGF-β (18, 19). 
In this report, we demonstrate that Smad7 overexpression delays the establishment and 
growth of melanoma bone metastases in a mouse model. Also, we determine that inhibition of 
the Smad cascade in melanoma cells represses the expression of a panel of TGF-β-dependent 
genes that was previously identified as critical for the establishment of bone metastases by 
breast cancer cells (17). 
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MATERIALS AND METHODS 
 
Cell cultures and reagents 
Melanoma cell lines WM239-A, WM1341-A, WM983-A, WM793, WM983-B, WM852, and 
1205Lu, kind gifts from Dr. M. Herlyn, Wistar Institute, Philadelphia, PA, have been 
previously described (14, 20, 21). They were grown in a composite medium (W489) 
consisting of three parts MCDB153 and one part L15 supplemented with 4% fetal calf serum 
(FCS) and antibiotics. Melanoma cell lines Dauv-1, 888-mel, 501-mel, SK-28, and FO-1 have 
been described previously (22). They were grown in RPMI medium supplemented with 10% 
FCS and antibiotics. Human lung fibroblasts (WI-26) were grown in DMEM containing 10% 
FCS and antibiotics. Generation of Smad7 expressing clones (S7.a and S7.c) and mock-
transfected cells has been described previously (15). All cells were grown at 37°C, 5% CO2 in 
a humidified atmosphere. The Smad3/4-specific reporter plasmid (CAGA)9-luc (23) was a gift 
from S. Dennler (INSERM U697). The pRL-TK vector was from Promega (Madison, WI). 
TGF-β1 was purchased from R&D Systems Inc. (Minneapolis, MN). The ALK5/TβRI 
inhibitor SB431542 was from Sigma-Aldrich (St-Louis, MO). 
 
Biochemical methods 
Protein extraction and Western blotting were performed as previously described (24). Anti-
Smad3 and anti-β-actin were from Zymed (San Francisco, CA) and Sigma-Aldrich, 
respectively. The rabbit anti-phospho-Smad2/3 antibody (25) was a generous gift from E. 
Leof (Mayo Clinic College of Medicine, Rochester, MN). Secondary anti-mouse and anti-
rabbit HRP-conjugated antibodies were from Santa-Cruz Biotechnology Inc. (Santa-Cruz, 
CA). 
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Generation of melanoma cell conditioned media 
3x106 cells of each cell type were plated in a 150-mm tissue culture dish and cultured in 16 ml 
W489 medium without FCS for 72 h. Supernatants were then collected and floating cells 
removed by centrifugation (420g, 5 min.). The corresponding cell layers were lysed and total 
protein concentration was determined to normalize each conditioned medium. 
 
Cells transfections and luciferase assays 
Melanoma cells were seeded in 24-well plates and transfected at approximately 70–80% 
confluency with the polycationic compound FugeneTM (Roche Diagnostics, Indianapolis, IN, 
USA) in fresh medium containing 1% FCS. TGF-β was added 4 h after transfection. WI-26 
fibroblasts were seeded in 24-well plates and transfected at approximately 70–80% 
confluency with Jet-PEI™ (Polyplus-Transfection, Illkirch, France) in fresh W489 medium 
without FCS. Conditioned media were added 4h after transfection. Following a 16-h 
incubation, cells were rinsed twice with phosphate-buffered saline and lysed in passive lysis 
buffer (Promega). Luciferase activities were determined with a Dual-Glo™ luciferase assay 
kit according to the manufacturer's protocol (Promega). 
 
Animal experiments 
The animal protocols for bone metastasis experiments were approved by the Institutional 
Animal Care and Use Committee at the University of Virginia in Charlottesville and were in 
accordance with the National Institutes of Health Guide for the Care and Use of Laboratory 
Animals. Athymic female nude mice 4 weeks of age were housed in laminar flow isolated 
hoods. Water supplemented with vitamin K and autoclaved mouse chow were provided ad 
libitum. Radiographs were taken under mouse anesthesia mixture (30% ketamine and 20% 
xylazine in 0.9% NaCl). Tumor inoculation into the left cardiac ventricle was performed on 
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anesthetized mice positioned ventral side up, as described previously (26). Briefly, the left 
cardiac ventricle was punctured percutaneously using a 26-gauge needle attached to a 1-ml 
syringe containing suspended tumor cells. Visualization of bright red blood entering the hub 
of the needle in a pulsatile fashion indicated a correct position in the left cardiac ventricle. 
Tumor cells (105 in 0.1 ml of PBS) were inoculated slowly over 1 min. Mice were followed 
by radiography for the development of bone lesions throughout the experiments.  Mice were 
x-rayed in a prone and lateral position using a Digital Faxitron MX-20 with digital camera 
(Faxitron x-ray, Wheeling, IL), as described previously (26). Radiographs where taken at 1X 
magnification and when a lesion was suspected, additional images with higher magnification 
(4X) were taken. Images were saved and lesion areas were measured and analyzed using 
MetaMorph software (Molecular Devices, Downingtown. PA).   
Bone Histology: Forelimb and hind limb bones were removed from mice at the time of 
experimental termination. Tissues were fixed in 10% neutral buffered formalin for 48h, 
decalcified in 10% EDTA for 2 weeks, processed using an automated tissue processor 
(Excelsior, Thermoelectric), and embedded in paraffin. The sections were stained with 
hematoxylin and eosin with orange G and phloxine to visualize new bone.  
 
RNA extraction and gene expression analysis 
In vitro experiments: Total RNA was isolated using an Rneasy™ kit (Qiagen GmbH, Hilden 
Germany). In vivo experiments: The femur and tibiae from mice were dissected and cleaned 
from adhering tissues. The cartilage ends were cut off and the tumor cells in the marrow 
cavity were flushed out using cold PBS in a syringe with a sterile needle. After centrifugation, 
cells were resuspended in RNAlater™ (Qiagen) and total RNA was isolated with TRIzol 
(Invitrogen, San Diego, CA), according to the manufacturer’s instructions. Genomic DNA 
contaminations were eliminated by DNAse I treament. One microgram of RNA from each 
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sample was reverse transcribed using the Thermoscript kit (InVitrogen) following the 
manufacturer’s instructions. The resulting cDNAs were then processed for Real-time PCR 
using SYBR Green technology. Reactions were carried out in a 7300 Real-time PCR System 
(Applied Biosystem) for 40 cycles (95°C for 15 sec/ 60 C for 1 min) after an initial 10-min 
incubation at 95°C. Primers were as follows: in vitro experiments, TGFβ1 (sense, 5'-
ctctccgacctgccacaga-3’ ; anti-sense, 5'-aacctagatgggcgcgatct-3’) ; TGFβ2 (sense, 5'-
ccfcccactttctacagaccc-3’ ; antisense, 5'-gcgctgggtgggagatgttaa-3’) ; TGFβ3 (sense,  5'-
ctggccctgctgaactttg-3’ ; antisense, 5'-aaggtggtgcaagtggacaga-3’) ; CXCR4  (sense, 5'-
cagtggccgacctcctctt-3’ ; antisense, 5'-cagtttgccacggcatca-3’) ; IL-11 (sense,  5'- 
actgctgctgctgaagactc-3’ ; anti-sense, 5'- ccacccctgctcctgaaata-3’) ; PTHrP (sense, 5'-
tttacggcgacgattcttcc-3’ ; anti-sense, 5'-ttcttcccaggtgtcttgag-3’) ; osteopontin (sense, 5'-
aggcagagcacagcatcgt-3’ ; 5'-ttggctgagaaggctgcaa-3’) ; in vivo experiments, IL-11 (sense, 5'- 
tgaagactcggctgtgacc-3’ ; anti-sense, 5'-cctcacggaaggactgtctc-3’) ; PTHrP  (sense, 5'- 
actcgctctgcctggttaga-3’ ; anti-sense, 5'-ggaggtgtcagacaggtggt-3’); CTGF (sense, 5'- 
gctaccacatttcctacctagaaatca-3’ ; anti-sense, 5'-gacagtccgtcaaaacagattgtt-3’). Target gene 
expression was normalized against the endogenous control genes cyclophylin A (sense, 5'- 
caaatgctggacccaacaca-3’ ; anti-sense, 5'-tgccatccaaccactcagtct-3’) or GAPDH (sense, 5'- 
gctcctcctgttcgacagtca-3’ ; anti-sense, 5'-accttccccatggtgtctga-3’). Data were analyzed using 
Applied Biosystems Sequence Detections Software (version 1.2.1).  
 
Statistical analyses 
Differences in osteolytic lesion areas between groups were determined by one-way ANOVA 
and two-way ANOVA. Kaplan-Meier survival curve data were analyzed by Logrank test. All 
results were expressed as mean ± SEM, and p<0.05 was considered significant (GraphPad 
Prism). 
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RESULTS AND DISCUSSION 
 
The role of TGF-β in melanoma progression and metastasis is controversial. Using a specific 
Smad-dependent transcription assay as well as Smad/DNA interaction assays based upon our 
original characterization of hCOL7A1 as a Smad3/4 gene target (27), we previously 
demonstrated that human melanoma cells secrete active TGF-β and exhibit both high 
constitutive, ligand-induced, Smad signaling (14). Subsequently, others have shown that 
TGF-β that is produced by melanoma cells contributes to peri-tumoral stroma remodeling, 
providing a survival advantage to melanoma cells (28). Contrasting with these results, it has 
also been proposed that the oncoproteins c-Ski and SnoN, known to interfere with Smad 
signaling (29), are expressed at high levels in melanoma cells, and may be responsible for the 
lack of growth inhibitory activity of TGF-β in these cells (30, 31). Recently, we demonstrated 
that overexpression of Smad7 in melanoma cells inhibits endogenous constitutive Smad 
signaling, reduces MMP secretion, and delays tumorigenicity both in vitro and in a model of 
sub-cutaneous tumor formation in nude mice (15). These apparently contradictory results 
regarding the role of autocrine TGF-β signaling in melanoma cells led us to re-evaluate the 
activation status of Smad signaling obtained in a number of available melanoma cell lines. 
Most transcriptional responses to TGF-β in the adult are mediated by Smad3/4 while it is 
generally accepted that Smad2 is critical during embryonic life (9). We thus focused our 
attention on Smad3/4 status and activation. As shown in Fig. 1A, the various cell lines tested 
exhibited variable basal levels of P-Smad3, a marker of TGF-β receptor activation (Fig. 1A). 
In all cases, exogenously added TGF-β further induced a dramatic elevation of P-Smad3 
levels, indicative of functional TGF-β receptor complexes (Fig. 1B). Transient cell 
transfection experiments with the Smad3/4-specific reporter construct (CAGA)9-lux (23) 
indicated that most cell lines responded to exogenous TGF-β with a robust transcriptional 
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response (Fig. 1C), indicative of functional TGF-β/Smad signal transduction cascade all the 
way from the cell membrane to the nucleus. These results are in full agreement with our 
initial observations (14), and consistent with the accepted concept of an autocrine and 
oncogenic role for TGF-β in late-stage carcinogenesis - reviewed in (32, 33).  
TGF-β expression is often increased in tumor cells and has been correlated with the advanced 
stage of melanoma progression (34). We thus wanted to determine whether an auto-regulatory 
loop controlled TGF-β expression in melanoma cells. Firstly, using quantitative real-time-
PCR, we determined that all melanoma cell lines available in the laboratory expressed the 
three TGF-β isoforms (not shown). TGF-β1 expression was predominant, with relative 
expression levels 10- to 20-fold higher than those for TGF-β3 (not shown). TGF-β2 was 
expressed at very low levels (100- to 1000-fold less than TGF-β1). These results are 
consistent with previously published observations (35). Incubation of some of these cell lines, 
selected based on their robust Smad-specific transcriptional response to TGF-β (see Fig. 1C) 
with exogenous TGF-β1 for 24h led to a consistently observed increase in the expression of 
TGF-β1, which was totally abrogated by the ALK5 inhibitor SB431542 (Fig. 2A). Expression 
of TGF-β2 mRNA was also induced by TGF-β1 treatment (Fig. 2B), however it only 
occurred in 50% of the cell lines tested (not shown). Again, incubation with the ALK5 
inhibitor SB431542 led to a complete abrogation of TGF-β2 induction by exogenous TGF-β1. 
Of note, no modulation of TGF-β3 expression was observed after either TGF-β1 or 
SB431542 treatment in any of the cell lines tested (not shown), suggesting its independence 
from Smad signaling.  
To determine whether melanoma cells secrete active TGF-β that could induce stroma 
activation, melanoma cell culture supernatants were studied for their capacity to activate the 
Smad pathway in fibroblasts in culture. Incubation of WI-26 human lung fibroblasts with 
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conditioned media from four distinct melanoma cell lines exhibiting constitutive Smad3/4 
activation and TGF-β1 expression induced both rapid and sustained Smad3 phosphorylation 
in WI-26 cells (Fig. 2C), and potent transactivation of the transfected (CAGA)9-lux construct 
(Fig. 2D). Incubation with W849 un-conditioned medium did not induce any of these TGF-β-
specific responses. Together, these results emphasize the fact that ligand-dependent 
constitutive activation of the Smad pathway in melanoma cells translates into production of 
active TGF-β that is highly capable of inducing both autocrine and paracrine (stromal) 
responses. 
It is expected from our data on the expression of the three TGF-β isoforms (see above) that 
TGF-β1, and TGF-β3, represent the majority of constitutively produced isoforms capable of  
driving Smad signaling in melanoma cells, even in the presence of a TβRI inhibitor. 
Furthermore, TGF-β1, and TGF-β2, is likely to be induced further in tissue environments rich 
in TGF-β, such as in late-stage cancer progression. 
 
We previously demonstrated that TGF-β promotes bone metastases from solid tumors such as 
breast cancer (16, 17, 19). Thus, given our recent data linking autocrine TGF-β signaling to 
melanoma aggressiveness (15), we decided to test the role of autocrine TGF-β signaling in 
melanoma metastases to bone by overexpressing the inhibitory Smad7 in a cell line with high 
endogenous Smad activity. For this purpose, we used 1205Lu cells as, (a), they exhibit high 
autonomous, ligand-induced, constitutive TGF-β/Smad signaling; (b), they exhibit a strong 
transcriptional response to exogenous TGF-β; (c) they are highly invasive in a Matrigel™ 
assay, and (d), they are highly tumorigenic in vivo (15). Furthermore, we previously 
demonstrated that Smad7 overexpression in 1205Lu melanoma cells reduces MMP-2 and 
MMP-9 production, as well as their capacity to invade Matrigel™ and to establish sub-
cutaneous tumors in nude mice (15).  
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In a proof-of-concept experiment, parental 1205Lu cells rapidly established bone metastases 
in a model of bone metastasis whereby tumor cells are inoculated into the left cardiac 
ventricle of nude mice. Reasons for using the model include the facts that 1) no model exists 
whereby primary melanoma tumors metastasize to bone; 2) the left cardiac ventricle model 
was established with melanoma lines (36); 3) the relevance to bone metastases has been 
consistently demonstrated in the literature (37, 38).  Specifically, this model addresses the 
process of metastasis from entry of tumor cells into the arterial circulation to the 
establishment of bone metastasis, and tumor-bone interactions. 
Bone metastases appeared to be mostly osteolytic, but some osteoblastic lesions were also 
found (Supplementary data, Fig. 1). In addition, soft tissue metastases to various organs –
adrenal glands, lungs, liver and skin - appeared in all test mice (n=6) 5-10 weeks after tumor 
inoculation (not shown).  
Next, 1205Lu melanoma cells were stably transfected with pcDNA-Smad7. In the first 
experiment, Smad7-overexpressing clones were compared with parental 1205Lu.  All mice 
(n=6) inoculated with parental 1205Lu cells developed osteolytic bone metastases 5 weeks 
post tumor inoculation (Fig. 3A, left panel), as well as metastases to adrenal glands and 
kidney (not shown). All mice bearing parental tumor cells had to be euthanized by week 5. In 
contrast, only 1 of 14 mice bearing Smad7-transfected 1205Lu cells (2 different clones, 7 
mice for each group) had osteolytic bone lesions on radiographs 10 weeks post tumor 
inoculation (Fig. 3A, center and right panels), and only 5/14 had been euthanized after 15 
weeks. The remaining animals were euthanized after 19 weeks because they all exhibited 
severe cachexia. Together, mice bearing Smad7-overexpressing 1205Lu tumors had 
significantly longer survival compared with mice bearing parental 1205Lu (Figure 3B). 
Quantitative computerized image analysis of osteolytic lesion area on radiographs indicated 
that at time of experiment termination (19 weeks), mice bearing Smad7-overexpressing 
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1205Lu had markedly less bone destruction than the mice inoculated with parental 1205Lu 
tumor cells after only 5 weeks (Figure 3C). This was remarkable in light of the fact that the 
mice bearing Smad7-overexpressing 1205Lu melanoma were euthanized 16-20 weeks 
following tumor inoculation compared with 5 weeks for mice bearing parental 1205Lu 
melanoma. 
 In a separate experiment, mice inoculated with Smad7-overexpressing 1205Lu melanoma 
cells (12 mice for each Smad7-overexpressing 1205Lu clone) were compared to mice 
inoculated with an empty vector-transfected control 1205Lu clone (11 mice) for the early 
establishment of bone metastases. For this purpose, the osteolytic lesion area was measured 
by x-ray, 4 and 6 weeks following intra-cardiac injection of the tumor cells. As shown in 
Figure 3D, while 10/11 mice injected with pcDNA-transfected tumor cells (EV) developed 
osteolytic metastases clearly detectable by x-ray as early as 4 weeks post-inoculation, none of 
the 24 mice inoculated with either of the Smad7-transfected clones had detectable bone 
lesions after 6 weeks.  
Taken together, these experiments demonstrate (a), that 1205Lu-Smad7 tumors cause 
significantly less and delayed bone metastases than parental and mock-transfected cells, and 
(b), that mice bearing these Smad7 tumors live longer.   
 
The contribution of TGF-β to bone metastasis of breast cancer cells has been ascribed to what 
has been viewed as a vicious cycle whereby tumors homing favorably to bone secrete 
osteolytic factors such as PTHrP and IL-11. The latter activate osteoblasts and osteoclasts to 
cause the degradation of the bone matrix and subsequent release of soluble factors, including 
TGF-β which, in turn, exacerbates tumor cells to produce more osteoclast-activating factors 
(19). A signature of TGF-β-inducible genes was identified, comprising CTGF, CXCR4 and 
IL-11, which, when overexpressed in non-metastatic cells, induced them to metastasize to 
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bone (17, 39). We thus screened several melanoma cell lines for their expression of TGF-β-
dependent target genes known to enhance metastases to bone from breast cancer cells, namely 
the osteolytic factors PTHrP and IL-11, the chemotactic receptor CXCR4, as well as CTGF 
and osteopontin. Quantitative RT-PCR analysis indicated that PTHrP, IL-11, CXCR4, and 
osteopontin mRNA steady-state levels were robustly increased in all cell lines treated with 
TGF-β in vitro (Table 2). The small molecule inhibitor ALK5/TβRI, SB431542, efficiently 
prevented the induction of PTHrP, IL-11, CXCR4 and osteopontin by TGF-β in all cell lines 
tested, and inhibited the basal expression levels of those genes, suggesting a role for autocrine 
TGF-β signaling in controlling their basal level of expression.  
 
Next, we examined whether Smad7 overexpression modulated the expression of bone 
metastasis-specific genes in 1205Lu cells in vitro and in vivo. As shown in Figure 4, stable 
Smad7 overexpression significantly reduced the extent of activation of IL-11, CXCR4, ONP, 
and to a lesser extent, PTHrP, gene expression by TGF-β in two distinct clones. To determine 
whether such downregulation of bone metastasis-specific genes by Smad7 occurred in vivo, 
RNA was extracted from bone and subcutaneous metastases that developed in mice after 
intra-cardiac inoculation of either mock- or Smad7-transfected 1205Lu melanoma cells. 
Semi-quantitative RT-PCR was used to determine the respective steady-state mRNA levels 
for IL-11, PTHrP, CTGF and GAPDH using primers specific for the human ortholog of each 
gene. Gene expression of bone metastases genes IL-11, PTHrP and CTGF in RNA derived 
from melanoma tumors differed depending on the metastatic site and whether the tumors 
expressed Smad7.  As shown in Figure 5, bone metastases from both Smad7 clones expressed 
little or no IL-11, PTHrP and CTGF while a bone metastasis from mock-transfected 1205Lu 
cells expressed these genes, all shown previously to drive the capacity of the latter to form 
bone metastases by MDA-MB-231 breast cancer (17). In contrast, IL-11, PTHrP and CTGF 
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were expressed in subcutaneous metastases regardless of whether the tumors overexpressed 
Smad7. One explanation for this differential expression may be due to different 
concentrations of TGFβ in the respective microenvironments. In bone, where TGFβ 
concentrations are high, Smad7 blocks the induction of bone metastases genes. In the 
subcutaneous site, PTHrP and CTGF may be induced by growth factors which do not signal 
through the TGFβ/Smad pathway. Thus, Smad7 does not block their induction. Together, 
these data suggest that attenuation of TGF-β signaling by Smad7 results in tissue-specific 
regulation of genes involved in the process of bone metastasis by melanoma cells.  It is thus 
likely that the pathophysiology of melanoma metastases to bone is similar to breast cancer, 
and that extinguished IL-11, CTGF and PTHrP expression likely contributes to the reduced 
capacity of Smad7-expressing clones to form bone metastases.   
We previously demonstrated that expression of a dominant-negative TβRII by MDA-MB-231 
resulted in a reduced capacity for these aggressive breast cancer cells to form bone 
metastases, due to lesser bone destruction, less tumor with fewer associated osteoclasts, and 
prolonged animal survival compared with controls (26). PTHrP, produced by tumor cell under 
the control of TGF-β signaling, was identified as critical for bone destruction. More recently, 
using both functional imaging of the Smad pathway in a mouse xenograft model and 
immunohistochemical analysis of human breast cancer bone metastases, Kang et al. provided 
evidence for active Smad signaling in both human and mouse bone metastatic lesions (40). 
Depletion of Smad4 using RNA interference demonstrated that the Smad pathway contributes 
to the formation of osteolytic bone metastases by MDA-MB-231 breast cancer cells, by 
controlling the expression of IL-11, CXCR4, and CTGF (41), thus reinforcing previous 
observations (40). Together, these studies suggest that a limited, yet highly significant gene 
signature is indicative of the bone metastasis potential of breast cancer cells. Many of these 
genes are regulated by TGF-β via the Smad signaling pathway. Consistent with these 
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collective findings, our results demonstrate that targeting endogenous TGF-β/Smad signaling 
in melanoma cells by mean of Smad7 overexpression is sufficient to dramatically delay bone 
metastasis formation in a mouse model of tumor cell inoculation in the left cardiac ventricle. 
Smad7 overexpression was shown to reduce the expression of the TGF-β/Smad-dependent 
bone metastasis signature genes, PTHrP, IL-11, CTGF, osteopontin or CXCR4. We do not 
provide functional evidence for a causal role for each of these target genes in the melanoma 
metastatic process to bone. Yet, our results are consistent with the hypothesis that TGF-β may 
promote melanoma bone metastases via mechanisms similar to those identified in breast 
cancer metastasis. 
The TGF-β/Smad pathway has also been implicated in other aspects of metastases. For 
example, Smad4 knock-down has reduced bone metastases due to MDA-MB-231 via 
interference with epithelial to mesenchymal transition (41). Moreover, it was recently shown 
that adenoviral delivery of Smad7 to JygMC(A) breast cancer cells significantly impairs their 
capacity to metastasize to lung and liver, possibly by altering their adhesive and migratory 
properties (42). TGF-β blockade has been effective to reduce breast cancer metastases to bone 
and other sites in mouse models (41, 43-47). In concordance, our results support the notion 
that blockade, or attenuation, of intracellular TGF-β signaling may be beneficial for the 
treatment of melanoma, another aggressive solid tumor able to generate bone metastases. 
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Table 1: Modulation of osteolytic factor gene expression by TGF-β in melanoma cells 
 
 
Sub-confluent melanoma cell cultures were pre-incubated for 6h in W489 medium without 
serum before stimulation with TGF-β1 (10 ng/ml), in the absence or presence of 5 μM 
SB431542 (or DMSO) added 1h before addition of the growth factor. Total RNA was 
analyzed by quantitative RT-PCR with primers specific for IL-11, PTHrP, CXCR4, and 
osteopontin (OPN). Values are corrected for cyclophilin A mRNA levels in the same 
samples and expressed as fold induction relative to untreated (ut) cultures, , after 8h (*) or 
24h or incubation, depending on the peak of gene expression induced by TGF-β. 
 
 
u
t
TGF-
β 
u
t
TGF-
β 0.55±0.03 19.28±2.06 0.32 0.46±0.07
35 1.1 
0.02 1.36±0.01 0.02±0.005 0.02 ± 0.01
IL-11 
68 1 
0.05 ± 0.03 1.66 ± 0.15 0.52 ± 0.14 0.46±0.13
31.9 0.9 
2.7 ± 0.41 11.9 ± 3.5 1.6 ± 
0.1 
0.4 ± 0.1 
4.4 0.25
dmso SB431542
cell line 
fold 
induction 
1205Lu
fold 
induction 
WM983
A fold 
induction 
WM983
B fold
induction 
WM85
2 
0.41 ± 0.005 1.12 ± 0.2 0.41 ± 0.01 0.33 ± 0.25
2.69 0.8 
0.08 0.41±0.01 0.03 ±0.005 N/A 
PTHrP 
5.1
0.08 ± 0.005 0.31 ± 0.03 0.12±0.02 0.13±0.01
3.9 1.1 
2.98 8.91 1.62 1.98
3 1.22
0.04 0.43 0.01 N/A 
1.47±0.03 35.4 ± 9.1 2.12 ± 0.01 2.01 ± 0.35
CXCR
4 
24.1 0.9 
1.38 14.37 0.78 1.49
10.4 1.9 
0.26 ± 0.03 0.59 ± 0.04 0.37 ± 0.03 0.33 ± 0.07
2.2 0.9 
0.65 
±0.08 
4.65±0.19 0.67±0.03 1.04±0.03
7.1 1.5 
ON
P 
69.9±2.4 155.3±7.5 92.6 ± 2.9 88.8 ± 1.3
2.2 0.9 
0.64 11.09 ± 0.16 0.38 ± 0.01 0.25±0.02
1.7 0.65
WM983
B fold 
induction 
WM85
2 
fold 
induction 
*1205L
u fold
induction 
WM983
A 
fold 
induction 
WM983
A fold 
induction 
WM983
B 
*1205L
u 
fold 
induction 
WM85
2 fold 
induction 
WM85
2 fold 
induction 
fold
induction 
WM983
B fold 
induction 
1205Lu
fold 
induction 
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Legends to Figures 
 
Figure 1 
A, Total protein extracts (60 μg) from unstimulated cultured melanoma cell lines were 
analyzed by Western blotting for phospho-Smad3 content. An anti β-actin antibody was 
used for normalization. 
B, Sub-confluent melanoma cell cultures were incubated for 6h in medium containing 1% 
serum. TGF-β1 (10 ng/ml) was added to the cultures 20 min before cell lysis for Western 
analysis (30 μg/lane) with specific antibodies directed against phospho-Smad3, Smad3, or 
β-actin. 
C, Subconfluent melanoma cell cultures were transfected with 0.4 μg of (CAGA)9-luc 
vector together with 0.2 μg of pRL-TK Renilla luciferase expression vector. Four hours 
after transfection, cultures were left untreated or were stimulated with TGF-β (10 ng/ml). 
Luciferase activities were measured in cell extracts 20h after transfection. Results are the 
means ± s.e.m. of three independent experiments. 
 
Figure 2 
Sub-confluent melanoma cell cultures were pre-incubated for 6h in medium containing 1% 
serum before stimulation with TGF-β1 (10 ng/ml), in the absence or presence of 5 μM 
SB431542 (or DMSO) added 1h before addition of the growth factor. Total RNA was 
analyzed by quantitative RT-PCR with primers specific for TGF-β1 (A) or TGF-β2 (B). 
Values are corrected for cyclophilin A mRNA levels in the same samples. 
C, Sub-confluent WI-26 human lung fibroblast cultures were incubated for 24 h in medium 
containing 0% serum, following which an equivalent volume of either W489 un-
conditioned or 1205Lu melanoma cell-conditioned medium was added. WI-26 cell layer 
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were then lyzed for Western analysis with specific antibodies directed against phospho-
Smad3 and Smad3. 
D, Subconfluent WI-26 fibroblast cultures were transfected with 0.4 μg of (CAGA)9-luc 
vector together with 0.2 μg of pRL-TK Renilla luciferase expression vector in W489 
medium without serum. Four hours after transfection, cultures were left untreated or were 
stimulated with TGF-β (10 ng/ml), or an equivalent volume of various melanoma cell-
conditioned media. Luciferase activities were measured in cell extracts 20h later. Results, 
expressed as relative reporter activation, are the means ± s.e.m. of three independent 
experiments. 
 
Figure 3 
A, Representative X-ray radiography of the hindlimbs of mice, 5 weeks (parental, n=6) or 
14 weeks (clones S7.a and S7.b, 7 mice each) after tumor cell inoculation. Osteolytic 
lesions are highlighted with yellow lines. Note the dramatic difference in both size and 
number of lesions generated by parental 1205Lu cells vs. Smad7-overexpressing clones. 
B, Survival of mice bearing S7.a (   ) and S7.c (   ) tumors was significantly longer than that 
of mice bearing parental 1205Lu cells (   ). 
C, Osteolytic lesion area (mm2) on radiographs was measured by computerized image 
analysis of forelimbs and hindlimbs at the time of death: 5 weeks post-inoculation for 
parental 1205Lu cells, 16 and 20 weeks after inoculation for S7.a and S7.c clones, 
respectively. Values represent mean +/- SEM (n=7). 
D, Osteolytic lesion area (mm2) on radiographs was measured by computerized image 
analysis of forelimbs and hindlimbs at 4 and 6 weeks post-inoculation for both pcDNA 
transfected 1205Lu cells (n=11,?) and clones overexpressing Smad7 (12 mice for each 
clone, ?, ?). Values represent mean +/- SEM. Note that lesion area was so small in both 
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Smad7-overexpressing 1205Lu-bearing mice that the data lines are indistinguishable from 
the x-axis. 
 
Figure 4 
Sub-confluent melanoma cell cultures (Mock-transfected and clones S7.a and S7.c) were 
pre-incubated for 6h in medium containing 1% serum before stimulation with TGF-β1. 
Twenty-four hours later, RNA was extracted and analyzed by quantitative RT-PCR with 
primers specific for IL-11 (A), PTHrP (B), CXCR4 (C), and OPN (D). Values are corrected 
for cyclophilin A mRNA levels in the same samples. 
  
Figure 5 
 RNA was extracted from either bone or soft tissue (subcutaneous) metastatic lesions 
derived from mock (M) and Smad7 (S7) inoculated tumor cells, and analyzed by semi-
quantitative RT-PCR with primers specific for human IL-11 (hIL-11), human PTHrP 
(hPTHrP), human CTGF (hCTGF) or human GAPDH (hGAPDH). The left lane 
corresponds to PCR reactions run without cDNA templates. As a positive control, we used 
mRNA from cultured human breast adenocarcinoma cell line MDA-MB-231, known to 
express the genes of interest. Mouse bone marrow RNA was used as a negative control to 
ascertain the tissue specificity of the primers. 
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